Apremilast Patent Expiration
Apremilast is used for treating psoriatic arthritis and plaque psoriasis with dosage titration and inhibiting PDE4. It was first introduced by Amgen Inc
Apremilast Patents
Given below is the list of patents protecting Apremilast, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Otezla Xr | US11752129 | Formulations Of Apremilast | May 27, 2042 | Amgen Inc |
| Otezla Xr | US11969409 | Formulations Of Apremilast | May 27, 2042 | Amgen Inc |
| Otezla Xr | US12427136 | Formulations Of Apremilast | May 27, 2042 | Amgen Inc |
| Otezla |
US10092541 (Pediatric) | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast | Nov 29, 2034 | Amgen Inc |
| Otezla |
US9872854 (Pediatric) | Methods for the treatment of psoriatic arthritis using apremilast | Nov 29, 2034 | Amgen Inc |
| Otezla |
US12576034 (Pediatric) | Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetylaminoisoindoline-1,3-Dione | May 30, 2034 | Amgen Inc |
| Otezla | US10092541 | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast | May 29, 2034 | Amgen Inc |
| Otezla | US9872854 | Methods for the treatment of psoriatic arthritis using apremilast | May 29, 2034 | Amgen Inc |
| Otezla Xr | US10092541 | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast | May 29, 2034 | Amgen Inc |
| Otezla | US12576034 | Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetylaminoisoindoline-1,3-Dione | Nov 30, 2033 | Amgen Inc |
| Otezla |
US7427638 (Pediatric) | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof | Aug 16, 2028 | Amgen Inc |
| Otezla | US7427638 | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof | Feb 16, 2028 | Amgen Inc |
| Otezla Xr | US7427638 | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof | Feb 16, 2028 | Amgen Inc |
| Otezla | US7893101 | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Dec 09, 2023
(Expired) | Amgen Inc |
| Otezla | US6962940 | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
Mar 19, 2023
(Expired) | Amgen Inc |
| Otezla | US7208516 | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar 19, 2023
(Expired) | Amgen Inc |
| Otezla | US7659302 | Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione |
Mar 19, 2023
(Expired) | Amgen Inc |
| Otezla | US8455536 | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar 19, 2023
(Expired) | Amgen Inc |
| Otezla | US8802717 | Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar 19, 2023
(Expired) | Amgen Inc |
| Otezla | US9018243 | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Mar 19, 2023
(Expired) | Amgen Inc |
| Otezla | US9724330 | Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar 19, 2023
(Expired) | Amgen Inc |
| Otezla | US6020358 | Substituted phenethylsulfones and method of reducing TNFα levels |
Oct 30, 2018
(Expired) | Amgen Inc |
Apremilast's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Apremilast:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
